Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 2
2019 4
2020 3
2021 2
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.
Yamaguchi O, Kasahara N, Soda H, Imai H, Naruse I, Yamaguchi H, Itai M, Taguchi K, Uchida M, Sunaga N, Maeno T, Minato K, Tomono H, Ogawara D, Mukae H, Miura Y, Shiono A, Mouri A, Kagamu H, Kaira K. Yamaguchi O, et al. Among authors: tomono h. Sci Rep. 2023 Nov 27;13(1):20848. doi: 10.1038/s41598-023-48210-5. Sci Rep. 2023. PMID: 38012343 Free PMC article.
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Tomono H, Taniguchi H, Fukuda M, Ikeda T, Nagashima S, Akagi K, Ono S, Umeyama Y, Shimada M, Gyotoku H, Takemoto S, Hisamatsu Y, Morinaga R, Tagawa R, Ogata R, Dotsu Y, Senju H, Soda H, Nakatomi K, Hayashi F, Sugasaki N, Kinoshita A, Mukae H. Tomono H, et al. Thorac Cancer. 2023 Oct;14(28):2890-2894. doi: 10.1111/1759-7714.15097. Epub 2023 Sep 7. Thorac Cancer. 2023. PMID: 37675546 Free PMC article.
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study.
Akagi K, Taniguchi H, Fukuda M, Yamazaki T, Ono S, Tomono H, Suyama T, Shimada M, Gyotoku H, Takemoto S, Yamaguchi H, Dotsu Y, Senju H, Soda H, Mizowaki T, Monzen Y, Ikeda T, Nagashima S, Tasaki Y, Nakamura D, Komiya K, Nakatomi K, Sasaki E, Hirakawa K, Mukae H. Akagi K, et al. Among authors: tomono h. Thorac Cancer. 2022 Aug;13(16):2404-2409. doi: 10.1111/1759-7714.14555. Epub 2022 Jul 8. Thorac Cancer. 2022. PMID: 35808894 Free PMC article.
Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis.
Takemoto S, Akagi K, Ono S, Tomono H, Honda N, Suyama T, Umeyama Y, Dotsu Y, Taniguchi H, Ogawara D, Senju H, Gyotoku H, Sugasaki N, Yamaguchi H, Nakatomi K, Fukuda M, Mukae H. Takemoto S, et al. Among authors: tomono h. Thorac Cancer. 2021 Sep;12(17):2300-2306. doi: 10.1111/1759-7714.14055. Epub 2021 Jul 13. Thorac Cancer. 2021. PMID: 34255933 Free PMC article.
Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.
Takemoto S, Fukuda M, Yamaguchi H, Ikeda T, Akagi K, Tomono H, Umeyama Y, Dotsu Y, Taniguchi H, Gyotoku H, Senju H, Kitazaki T, Nakatomi K, Nagashima S, Fukuda M, Kinoshita A, Soda H, Mukae H. Takemoto S, et al. Among authors: tomono h. Thorac Cancer. 2020 Feb;11(2):389-393. doi: 10.1111/1759-7714.13279. Epub 2019 Dec 18. Thorac Cancer. 2020. PMID: 31851428 Free PMC article.
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.
Ikeda T, Takemoto S, Senju H, Gyotoku H, Taniguchi H, Shimada M, Dotsu Y, Umeyama Y, Tomono H, Kitazaki T, Fukuda M, Soda H, Yamaguchi H, Fukuda M, Mukae H. Ikeda T, et al. Among authors: tomono h. Thorac Cancer. 2020 Jul;11(7):1972-1978. doi: 10.1111/1759-7714.13490. Epub 2020 May 28. Thorac Cancer. 2020. PMID: 32462731 Free PMC article. Clinical Trial.
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor.
Dotsu Y, Yamaguchi H, Fukuda M, Suyama T, Honda N, Umeyama Y, Taniguchi H, Gyotoku H, Takemoto S, Tagawa R, Ogata R, Tomono H, Shimada M, Senju H, Nakatomi K, Nagashima S, Soda H, Ikeda H, Ashizawa K, Mukae H. Dotsu Y, et al. Among authors: tomono h. J Clin Med. 2021 Sep 17;10(18):4221. doi: 10.3390/jcm10184221. J Clin Med. 2021. PMID: 34575334 Free PMC article.
Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
Shimada M, Yamaguchi H, Fukuda M, Tomono H, Honda N, Dotsu Y, Taniguchi H, Gyotoku H, Senju H, Takemoto S, Ikeda T, Nakatomi K, Nakamura Y, Nagashima S, Yamazaki T, Mukae H. Shimada M, et al. Among authors: tomono h. Cancer Chemother Pharmacol. 2019 Nov;84(5):1059-1064. doi: 10.1007/s00280-019-03940-0. Epub 2019 Sep 5. Cancer Chemother Pharmacol. 2019. PMID: 31486872 Clinical Trial.
14 results